Intro
If the kidney has been paying the bill quietly and the brain has been paying it slowly, the heart is the organ where the bill has been most visible — and most thoroughly misread.
The heart was the first organ to receive serious attention for the lipid story.
Long before the kidney connection was understood, long before the brain connection was suspected, cardiology had already named cholesterol as a player in atherosclerosis, named LDL as the carrier worth measuring, and put lipid management on the agenda of every primary care visit in the developed world.
That work mattered. It saved lives. The cardiology field deserves credit for getting lipid biology onto the medical map at all, and for building the clinical infrastructure that has made lipid management a routine part of preventive care.
But the same work that established LDL as the focus of attention has, over time, revealed something the original framework did not anticipate.
The signal cardiology has been measuring is real. It is also incomplete.
---
What the LDL Story Got Right
LDL particles do contribute to atherosclerosis. That is not in dispute. The mechanism by which LDL particles enter the arterial wall, become oxidized, recruit inflammatory cells, and contribute to plaque formation has been mapped in extraordinary detail. Therapies that lower LDL — statins, ezetimibe, PCSK9 inhibitors — have been shown across many large trials to reduce cardiovascular events.
That is real science, and it has produced real patient benefit.
If the lipid story ended at LDL, the existing framework would be sufficient. The numbers we measure would match the disease we treat, and the residual risk that remains after LDL is optimized would be small.
But the residual risk is not small.
---
The Gap the Field Has Been Trying to Explain
Patients who reach their LDL targets continue to have cardiovascular events. Patients who are taking statins, sometimes high-dose statins, sometimes combinations of lipid-lowering agents, continue to progress. The reduction in events that LDL-lowering therapy produces is real, but it leaves a substantial fraction of risk on the table.
This residual risk has been one of cardiology's most persistent puzzles. The field has tried to address it in several ways. By pushing LDL targets lower. By adding agents. By measuring particle number rather than cholesterol content. By looking at ApoB instead of LDL-C.
These refinements have helped. They have also pointed, increasingly, in the same direction.
The signal that explains a meaningful portion of residual risk is not a refinement of LDL.
It is the signal upstream of LDL.
---
What the Population Data Have Been Saying
The same lipid pattern that predicts kidney disease — elevated triglycerides, low HDL, the signature of an active hepatic export — also predicts cardiovascular events.
The 911,000-person UK cohort that found triglycerides and HDL-C predicting advanced CKD found the same predictive relationship for cardiovascular outcomes. The atherogenic dyslipidemia pattern — high triglycerides, low HDL, small-dense LDL particles, elevated ApoB — has been recognized in cardiology for years as a high-risk profile. Mendelian randomization studies have shown that the genetic variants that raise triglycerides and triglyceride-rich lipoproteins are causally associated with cardiovascular disease, independently of LDL.
The cardiology field has, in effect, been working its way toward the same conclusion the kidney literature reached. The downstream marker is LDL. The upstream signal is the triglyceride-rich lipoprotein pattern that reflects what the liver is doing.
Cardiology built its framework around the consequence. The cause has been visible the whole time, in the same lab panel, in the same patients.
---
The Reframe
This is where the heart story joins the rest of the series.
The atherosclerotic process that produces cardiovascular events is not a story that begins in the artery. It is a story that begins in the liver, in the same hepatic state that has been producing the lipotoxic environment the kidney and the brain have been living in.
When the liver is in that state, it exports more triglyceride-rich lipoproteins. Those particles undergo modification and remodeling in circulation. Some become the small-dense LDL that cardiology has long recognized as particularly atherogenic. Others contribute directly to vascular injury through their lipolysis products. The HDL fraction, in this same metabolic environment, becomes less functional. The particle ratios that have been described as "atherogenic dyslipidemia" are the vascular signature of the same hepatic state the rest of this series has been describing.
The artery is downstream. The liver is upstream. And VLDL, sitting on the lab panel, has been reporting the upstream condition all along.
This does not displace the LDL story. LDL still matters. Lowering LDL still produces benefit. But understanding LDL as the consequence of an upstream signal, rather than as the central driver of the disease, changes what we look at, what we measure, and what we treat.
---
The Same Lesson, Across Three Organs
The kidney post made one version of this argument. The brain post made another. The heart post is making the third.
In each case, the field built its framework around what it could see at the organ — declining eGFR in the kidney, plaques and tangles in the brain, atherosclerotic plaque in the artery. In each case, the framework worked well enough to produce real progress, but left a substantial gap that the field has been trying to close.
In each case, the gap closes when the liver is added to the picture. The hepatic state that elevates VLDL is the upstream signal that explains a significant portion of what the organ-specific frameworks have not been able to account for.
The cardiology lens has done important work and is incomplete. The nephrology lens has done important work and is incomplete. The neurology lens has done important work and is incomplete.
What completes them is the same thing.
The liver, and the signal it has been quietly sending all along.
---
Where This Leaves the Lab Panel
If you are a clinician or a patient looking at a standard lipid panel, the practical implication is straightforward.
The LDL number is real and worth attention. So is the triglyceride number. So is the HDL number. But the question worth asking, in addition to the LDL question, is the upstream question.
What is the liver doing to produce the pattern I am looking at?
The VLDL number — calculated cleanly from a directly measured LDL-C, as we discussed in the second post — is the most direct readout of that question available on a standard panel. It is the signal cardiology has been adjacent to for forty years, in the lab panel it has been ordering all along.
The next post will look at the organ that closes the loop, where the same hepatic state begins to feed itself.
The pancreas.